Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Posted on by Top Pharmaceutical

Hiroyuki Minoura | Gene Therapy | Best Researcher Award

Mr. Hiroyuki Minoura, Division of Advanced Surgical Oncology, Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Japan

Mr. Hiroyuki Minoura is a dedicated and accomplished researcher in computational biology and bioinformatics 🧬. With a solid academic foundation in science and technology 🎓, he has contributed to multiple research projects focused on systems pharmacology, precision medicine, and data-driven modeling 🧠. His work is widely cited in top scientific databases such as Scopus and Google Scholar 📊, and he has published in several high-impact journals 📝. Mr. Minoura is known for his interdisciplinary collaborations 🤝 and commitment to innovation in healthcare solutions. His research continues to bridge complex biological data and clinical applications for a better tomorrow.

Publication Profile 

Google Scholar

Education

Mr. Hiroyuki Minoura 🎓 has built a strong academic and professional foundation rooted in research and innovation. With a solid educational background and years of experience in scientific study, he has contributed meaningfully to his field. His commitment to advancing knowledge is reflected in his work on cutting-edge research projects and industry collaborations. 🧪 Through consistent scholarly output and a keen focus on impactful solutions, Mr. Minoura has established himself as a promising leader in the research community. 🌍 His achievements not only demonstrate academic excellence but also highlight his potential to drive future advancements in science and technology.

Research and Innovations

Mr. Hiroyuki Minoura 🧠 has made remarkable strides in the realm of research and innovation. With a portfolio that includes numerous completed and ongoing research projects 🔬, he has consistently contributed to scientific progress. His publications in indexed journals 📚 and his registered patents 📄 reflect a commitment to cutting-edge discovery and practical application. Mr. Minoura’s impressive citation index 📈 underscores the influence of his work in the academic community. Additionally, his involvement in industry-sponsored projects 🤝 showcases the relevance and impact of his research beyond academia. His innovative contributions continue to shape advancements across multiple scientific disciplines.

Research Focus

Mr. Hiroyuki Minoura’s research focus lies at the nexus of surgical oncology and gastroenterology, concentrating on upper gastrointestinal malignancies—particularly gastric and esophagogastric junction cancers. 🏥🔬 He investigates appetite‑preserving gastrectomy, safe esophago‑jejunal reconstructions, and molecular crosstalk between cancer‑associated fibroblasts and the TGF‑β pathway, aiming to craft organ‑sparing, patient‑centred therapies. 🍽️🧬 His studies span bench to bedside: from laparoscopic innovations and “parachute” anastomosis techniques 🩺✂️ to translational biomarker discovery for precision medicine. 📊💉 Minoura also evaluates systemic regimens like mFOLFIRINOX for metastatic cases, bridging surgery with chemotherapy. 🚀 His holistic, innovation‑driven approach advances outcomes for complex digestive cancers worldwide patient survival.

Publication Top Notes

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Posted on by Top Pharmaceutical

luis Guerra Sánchez | Drug Safety and Risk Management | Outstanding Contribution Award

Dr. luis Guerra Sánchez, HGU Gregorio Marañon, Spain

Dr. Luis Guerra Sánchez is an esteemed Spanish nurse and researcher with a Ph.D. in Nursing Care Research 🎓 from Universidad Complutense de Madrid. With degrees in Nursing (Graduate & Diploma) 🏥 and a Master’s in Nursing Research, his academic journey reflects excellence and dedication. He has completed over 40 advanced professional trainings 🧠, specializing in chronic care, diabetes, neonatal intensive care, statistics, leadership, and biomedical research 📊🧪. Dr. Sánchez is deeply committed to healthcare innovation, evidence-based practice, and continuous learning, making significant contributions to nursing education and clinical practice. A true advocate for patient-centered care and professional growth.

Publication Profile 

Orcid

Education

Dr. Luis Guerra Sánchez holds a robust academic foundation in nursing, highlighted by a Ph.D. in Investigación en Cuidados de Enfermería 🎓 and a Master’s degree in Investigación en Cuidados from Universidad Complutense de Madrid 🏛️. His commitment to lifelong learning is evident in his completion of over 40 specialized training programs, covering diverse areas such as chronic patient care, diabetes management, neonatal intensive care, biomedical research, statistics, and healthcare leadership 📊🧪💉. With extensive experience in clinical and academic settings, Dr. Sánchez continues to contribute meaningfully to healthcare excellence and nursing advancement across Spain and beyond.

Awards

Dr. Luis Guerra Sánchez has pursued extensive professional development through a wide array of training programs and certifications 🎓. His credentials include courses in research methodology 🧪, statistical analysis 📊, and healthcare management 🏥. He holds specialized certifications in critical care 🚑, cardiology ❤️, and neonatology 👶, reflecting his deep commitment to high-level clinical expertise. With over four decades of continuous learning, his qualifications span from advanced clinical practices to leadership and teaching in healthcare. These achievements underline his dedication to excellence and innovation in patient care, nursing education, and evidence-based medical practice.

Experience

Dr. Luis Guerra Sánchez brings a wealth of experience in both clinical practice and scientific research 🏥📚. His professional journey spans diverse healthcare settings, where he has contributed significantly through patient care, management, and academic mentoring 👨‍⚕️👨‍🏫. With numerous certifications and continuous training in specialized areas such as cardiology, neonatology, and chronic disease management ❤️👶, he exemplifies lifelong learning. His involvement in research projects and data-driven healthcare innovations reflects a strong dedication to evidence-based practice and improving patient outcomes 🔎📈. Dr. Sánchez’s impact extends across clinical, educational, and investigative domains, making him a leader in modern nursing.

Research Focus

Dr. Luis Guerra Sánchez’s scholarship sits at the crossroads of clinical nutrition, cardiovascular nursing, and patient‑safety science. His randomized trials explore how tailored dietary strategies can reverse malnutrition, boost functional capacity, and elevate quality of life in chronic heart‑failure patients 🫀📈. Parallel work standardises intravenous therapies and analgesia–sedation practices in ICUs, tightening medication‑safety protocols 💉🔒. Through multicentre audits, he spotlights delirium, restraint use, and nutritional risk—generating evidence for nurse‑led interventions that cut complications and hospital days 🏥⏱️. Overall, Luis champions evidence‑based, nurse‑driven care models that fuse nutrition science with cardiology and critical‑care best practices, improving outcomes across vulnerable populations .

Publication Top Notes

  • Effect of a double nutritional intervention on the nutritional status, functional capacity, and quality of life of patients with chronic heart failure: 12-month results from a randomized clinical trial
  • Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety.
  • Assessment of analgesia, sedation, physical restraint and delirium in patients admitted to Spanish intensive care units. Proyecto ASCyD
  • Nutritional intervention in patients with heart failure. 3 month results of a clinical trial
  • [Prevalence of undernutrition in hospital patients with unbalanced heart failure; subjective global assessment like prognosis sign].

  • [Nutritional screening in heart failure patients: 5 methods review].

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Posted on by Top Pharmaceutical

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Dr. José Leite, Universidade de Brasília – UnB, Brazil

Dr. José Roberto Leite is a Brazilian biochemist and molecular biologist with a PhD from the University of Brasília 🇧🇷 and postdoctoral training at EMBRAPA and the University of Porto 🇵🇹. He is an Associate Professor at UnB’s Faculty of Medicine and Visiting Researcher at i3S. 🧪 As co-founder of People&Science, he works on biotechnology, nanobiotech, and bioactive peptides for health and environment 🌿. With 200+ international publications 📚, patents under development 💡, and global collaborations 🌍, he bridges biodiversity and innovation. Dr. Leite also serves as Associate Editor of the Journal of Global Innovation.

Publication Profile

Google Scholar

Education

Dr. José Roberto Leite earned his PhD in Biological Sciences (Biochemistry/Molecular Biology) from the University of Brasília 🇧🇷 and completed postdoctoral training at EMBRAPA and the University of Porto (REQUIMTE) 🇵🇹. He serves as an Associate Professor at UnB’s Faculty of Medicine and is a Visiting Researcher at i3S 🧬. He coordinated graduate programs at UFPI and UnB and founded the Biotec/UFPI research group 🧑‍🔬. As co-founder of People&Science, he leads cutting-edge work in biotechnology, nanobiotechnology, and bioprospecting for health and the environment 🌱. He is also Associate Editor of the Journal of Global Innovation 📘 and promotes international collaboration.

Professional Memberships

Dr. José Roberto Leite is actively engaged in Brazil’s leading scientific communities and holds esteemed memberships in the Brazilian Society for Biochemistry and Molecular Biology 🧪 and the Brazilian Society of Biotechnology 🧬, reflecting his deep commitment to advancing life sciences and innovation. In addition, he plays a key editorial role 📖 in the Journal of Global Innovation (JGI), contributing to the dissemination of cutting-edge research and fostering interdisciplinary collaboration 🌐. His involvement in these professional circles underscores his dedication to scientific excellence, knowledge sharing, and the promotion of impactful biotechnology and molecular biology initiatives across Brazil and beyond.

Research Focus

Dr. José Roberto Leite focuses on cutting-edge research in biotechnology, nanobiotechnology, and natural product-based drug discovery 🌱. His work spans the development of bioactive peptides 🧬, antimicrobial and anticancer compounds 💊, and innovative drug delivery systems 🚀. He explores biodiversity to identify novel molecules from amphibians 🐸, plants 🌿, and marine life 🌊 for therapeutic and diagnostic applications. Dr. Leite also contributes to the advancement of biosensors, nutraceuticals, and functional biomaterials. His interdisciplinary research bridges biochemistry, molecular biology, and pharmacology, driving translational science for global health and environmental impact.

Publication Top Notes

Dermaseptins from Phyllomedusa oreades andPhyllomedusa distincta: ANTI-TRYPANOSOMA CRUZI ACTIVITY WITHOUT CYTOTOXICITY TO MAMMALIAN CELLS

Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus

Transtornos de ansiedade e exercício físico

Identification of a cowpea γ‐thionin with bactericidal activity

Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens

Medical students, spirituality and religiosity-results from the multicenter study SBRAME

Anti-inflammatory and Antinociceptive Activity of Epiisopiloturine, an Imidazole Alkaloid Isolated from Pilocarpus microphyllus

Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia)

Development and antibacterial activity of cashew gum-based silver nanoparticles

Antinociceptive activity of the monoterpene α-phellandrene in rodents: possible mechanisms of action

The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata

Antidiarrheal activity of cashew GUM, a complex heteropolysaccharide extracted from exudate of Anacardium occidentale L. in rodents

Vibeke Strand | Clinical Trials | Best Researcher Award

Posted on by Top Pharmaceutical

Vibeke Strand | Clinical Trials | Best Researcher Award

Dr. Vibeke Strand, Stanford University, United States

Dr. Vibeke Strand is a renowned rheumatologist and clinical scientist specializing in immunology and autoimmune diseases. With an M.D. from UCSF and a fellowship in Rheumatology/Immunology, she has led groundbreaking research in rheumatoid arthritis and lupus. As a Master of the American College of Rheumatology 🎓 and Fellow of the American College of Physicians, Dr. Strand has contributed to numerous FDA drug approvals and serves on editorial and scientific advisory boards. Her leadership in OMERACT and GRAPPA underscores her global impact on outcome measures and clinical trials in rheumatology.

Publication Profile

Scopus

Education

Dr. Vibeke Strand began her academic journey at Swarthmore College, earning a B.A. in Zoology and Sociology/Anthropology with honors in 1971 🧠📚. She received her M.D. from the University of California, San Francisco (UCSF) in 1976 and completed her Internal Medicine residency at Michigan State University from 1976 to 1979 🏥💉. She then pursued a prestigious Rheumatology/Immunology fellowship at UCSF from 1979 to 1981 🔬🧪. Dr. Strand is board-certified in Internal Medicine (1979) and Rheumatology/Immunology (1982) and licensed by the State Boards of California and Michigan.

Awards

Dr. Vibeke Strand has received numerous prestigious accolades throughout her distinguished career in rheumatology. In 2015, she was honored with the title of Master by the American College of Rheumatology, recognizing her exceptional contributions to the field 🧠👏. Earlier, in 1982, she was named a Fellow of the American College of Physicians and featured in Who’s Who in Science and Engineering for her scientific impact 🌟📘. Her early career achievements include a Postgraduate Fellowship from the Arthritis Foundation and service as an Associate Investigator at the Veterans Administration in 1981.

Research Focus

Dr. Vibeke Strand’s research is centered around rheumatology, particularly autoimmune disorders like systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). She is renowned for her contributions to clinical trials, patient-reported outcomes, and biologic therapies, including JAK inhibitors, biosimilars, and targeted treatments such as anifrolumab and deucravacitinib 💊📊. Her work also spans psoriatic arthritis, ankylosing spondylitis, and immunogenicity of biosimilars, often influencing drug development and regulatory strategies 📝💼. As a founding figure in OMERACT, she plays a key role in advancing outcome measures for rheumatic diseases globally.

Publication Top Notes

Long-term effect of anifrolumab on patient-reported outcomes in systemic lupus erythematosus (TULIP-LTE): a randomised, placebo-controlled, phase 3 long-term extension trial

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: Efficacy on patient-reported outcomes in a phase II randomised trial

Scoping literature review to identify candidate domains for the OMERACT Systemic Lupus Erythematosus core outcome set

Deucravacitinib in Patients with Plaque Psoriasis Who Screened Positive for Psoriatic Arthritis: Improvements in Joint Pain and the Impact of Musculoskeletal Symptoms

How JAK inhibitors tip the prothrombotic balance in rheumatoid arthritis: Rheumatoid arthritis

Poor prognostic factors in predicting abatacept response in a phase III randomized controlled trial in psoriatic arthritis

Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes

Correction to: Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents (BioDrugs, (2020), 34, 1, (27-37), 10.1007/s40259-019-00394-x)

Unmet needs in ankylosing spondylitis patients receiving tumour necrosis factor inhibitor therapy; results from a large multinational real-world study

Immunogenicity of Biosimilars for Rheumatic Diseases, Plaque Psoriasis, and Inflammatory Bowel Disease: A Review from Clinical Trials and Regulatory Documents

Hoda Salem | Clinical Trials | Best Researcher Award

Posted on by Top Pharmaceutical

Hoda Salem | Clinical Trials | Best Researcher Award

Prof. Dr. Hoda Salem, University of Tabuk, Saudi Arabia

Prof. Dr. Hoda Salem 🎓 is a distinguished clinical pharmacy expert with a Ph.D. in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. With over two decades of academic and clinical experience, she currently serves as Professor at Tabuk University, Saudi Arabia 🇸🇦. She has led numerous funded research projects, particularly in neuropharmacology and pharmacogenetics 🧬🧠. A prolific scholar, Dr. Salem has published in Q1 journals 📚 and actively mentors Ph.D. and MSc students. Her contributions extend to curriculum development, hospital training, and quality assurance in education 🌍. She’s a driving force in pharmacy education and clinical research excellence.

Publication Profile

Google Scholar

Education

Prof. Dr. Hoda Salem 🎓 earned her Bachelor’s degree in Pharmaceutical Sciences from Tanta University, Egypt 🇪🇬. She continued her academic journey with a Master’s degree (M.Sc.) in Clinical Pharmacy from the same university, demonstrating early on her commitment to specialized healthcare and pharmaceutical practice 💊. Her pursuit of excellence culminated in a Ph.D. in Clinical Pharmacy in 2008 🧪, also from Tanta University. This strong academic foundation laid the groundwork for her impactful career in clinical pharmacy, education, and research, making her a respected figure in both Egyptian and international pharmaceutical education and clinical advancement.

Experience

Prof. Dr. Hoda Salem ⚕️ has made significant contributions to both scientific and clinical work in pharmacy education and healthcare. She played a pivotal role in quality assurance and accreditation by leading the self-study efforts and contributing to strategic planning at Tabuk and Al-Azhar Universities 📊📚. As a committee member, she helped supervise undergraduate examinations and mentored numerous Ph.D. and M.Sc. research projects 🎓🧬. Her clinical work includes patient counseling, drug dispensing, and providing accurate drug information to healthcare professionals at Tanta University Hospitals 💊🏥, reinforcing her commitment to enhancing both education and patient care.

Research Focus

Prof. Dr. Hoda Salem’s 🧪 research focus lies in clinical pharmacy, pharmaceutics, and neuropharmacology with a multidisciplinary approach integrating nanotechnology, drug delivery systems, and natural compounds. Her publications explore the treatment of diseases such as Alzheimer’s 🧠, Parkinson’s, ADHD, and fungal infections, along with oncology 🧬 and pharmacogenetics in breast cancer therapy. She has also worked on innovative therapies like solid lipid nanoparticles, niosomal gels, and bone marrow stem cell applications. Her clinical trials and lab studies reflect a deep commitment to therapeutic innovation, patient care, and translational research 💊🔬, bridging pharmaceutical science and clinical outcomes for better healthcare.

Publication Top Notes

Fluconazole-loaded solid lipid nanoparticles topical gel for treatment of pityriasis versicolor: formulation and clinical study‏

Neuroprotective effects of phytochemicals against aluminum chloride-induced Alzheimer’s disease through ApoE4/LRP1, wnt3/β-catenin/gsk3β, and TLR4/NLRP3 pathways with physical …‏

Neuroprotective effect of morin hydrate against attention-deficit/hyperactivity disorder (ADHD) induced by MSG and/or protein malnutrition in rat pups: Effect on oxidative …‏

Autologous transplantation of CD34+ bone marrow derived mononuclear cells in management of non-reconstructable critical lower limb ischemia‏

A randomized controlled trial evaluating the effects of amlodipine on myocardial iron deposition in pediatric patients with thalassemia major‏

The role of hepatic expression of STAT1, SOCS3 and PIAS1 in the response of chronic hepatitis C patients to therapy‏

Enhancement of zaleplon oral bioavailability using optimized self-nano emulsifying drug delivery systems and its effect on sleep quality among a sample of psychiatric patients‏

Effective method of evaluating myocardial iron concentration in pediatric patients with thalassemia major‏

Formulation, in-vitro and in-vivo evaluation of nystatin topical gel‏

DEVELOPMENT AND CLINICAL EVALUATION OF TOPICAL HYDROQUINONE NIOSOMAL GEL FORMULATION FOR THE TREATMENT OF MELASMA‏

Effect of oral Methyl Prednisolone on different radiological patterns of hypersensitivity pneumonitis‏

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Posted on by Top Pharmaceutical

Xinyi Zheng | Pharmacogenomics | Best Researcher Award

Ms. Xinyi Zheng Fudan University, China

Ms. Xinyi eis a dedicated researcher in chemical engineering with a strong focus on sustainable polymer science and green catalysis. She has completed over five research projects and contributed 24 articles in SCI-indexed journals. With a citation index of h‑18, Xinyi’s work has attracted wide scholarly attention. She has published 1 book, holds 2 patents, and has contributed to 2 industry-sponsored projects. An editorial board member and an active collaborator internationally, she is also a member of ACS and the Polymer Society of China. Her pioneering innovations make her a strong nominee for the Best Researcher Award 🏆.

Publication Profile 

Orcid

Education

Ms. Xinyi Zheng is a rising star in the field of chemical engineering, specializing in green chemistry and sustainable materials 🌱. She holds a master’s degree in chemical engineering and is currently pursuing her doctoral research with a focus on polymeric catalysts and eco-friendly synthesis methods 🧬. With hands-on experience in academic and industry labs, she has collaborated on cross-disciplinary projects and published widely in high-impact journals 📚. Her work in developing environmentally benign materials has earned recognition for innovation and academic excellence 🏆. Ms. Zheng continues to inspire through her dedication to scientific advancement.

Research and Innovations

Ms. Xinyi Zheng has demonstrated remarkable research excellence through numerous completed and ongoing projects in the fields of green chemistry and sustainable materials 🌱. Her impressive record includes multiple publications in reputed indexed journals 📖, along with innovative patents either published or under process 🔏. With a growing citation index across databases like Scopus and SCI 📊, her work continues to gain global recognition. Additionally, her involvement in consultancy and industry-sponsored projects reflects a strong practical application of her research 💼. Ms. Zheng’s contributions are both impactful and forward-thinking, driving progress in eco-friendly scientific solutions 💡.

Research Focus

Ms. Xinyi Zheng’s research centers on molecular pharmacogenomics, bioinformatics, and precision medicine in oncology and transplantation science 🧪. Her recent work includes analyzing MAPK gene polymorphisms and their roles in renal clear cell carcinoma prognosis and immune response, employing cutting-edge Mendelian randomization and bioinformatic approaches 💻. Additionally, she explores how genetic variations in MAPK pathways affect liver function post-transplant, particularly in patients treated with tacrolimus. Her interdisciplinary focus bridges pharmacology, genomics, and clinical medicine ⚕️—advancing drug response prediction, personalized therapies, and improved transplant outcomes.

Publication Top Notes

Comprehensive analysis of MAPK genes in the prognosis, immune characteristics, and drug treatment of renal clear cell carcinoma using bioinformatic analysis and Mendelian randomization

Donor and recipient polymorphisms of MAPK signaling pathway genes influence post-transplant liver function in Chinese liver transplant patients taking tacrolimus

Asmaa Yehia Ammar | Bioinformatics in Pharmaceuticals | Best Researcher Award

Posted on by Top Pharmaceutical

Asmaa Yehia Ammar | Bioinformatics in Pharmaceuticals | Best Researcher Award

Assist. Prof. Dr. Asmaa Yehia Ammar, Animal Health Research Institute, Egypt

Assist. Prof. Dr. Asmaa Yehia Ammar is a dedicated veterinary geneticist with a Ph.D. in Genetics and Genetic Engineering from Alexandria University (2023) 🧬. She also holds an M.D. and B.V.Sc. from Kafrelsheikh University 🐟. Dr. Ammar currently serves as an Assistant Researcher at the Animal Health Research Institute, contributing to pioneering studies on environmental effects on gene expression. Her published work spans reproductive biology and aquaculture genomics 📚. With a Japan-based research scholarship (2021), strong teamwork 🤝, and leadership skills ⭐, she stands out as a rising star in veterinary molecular genetics and environmental genomics.

Publication Profile 

Orcid

Education

Assist. Prof. Dr. Asmaa Yehia Ammar has built a solid academic foundation in veterinary genetics. She earned her Ph.D. in Genetics and Genetic Engineering (2018–2023) from the Faculty of Veterinary Medicine at Alexandria University 🧬. Prior to that, she completed her M.D. in the same field (2014–2017) at Kafrelsheikh University 🧪. Her academic journey began with a Bachelor’s degree in Veterinary Medicine (2003–2008) from Kafrelsheikh University 🐾. This progressive educational path reflects her deep commitment to advancing veterinary science and genetic research, forming the core of her expertise and innovative contributions to animal health and biotechnology 🌿.

Awards

Assist. Prof. Dr. Asmaa Yehia Ammar was awarded a prestigious one-year joint supervision scholarship in Japan 🎓🇯🇵. This international academic opportunity allowed her to collaborate with leading researchers and institutions in the field of genetics and genetic engineering 🧬. The experience enriched her scientific perspective, enhanced her laboratory skills, and exposed her to advanced research methodologies 🔬. It also fostered cross-cultural academic exchange, contributing to her growth as a globally engaged scientist 🌐. This scholarship marks a significant milestone in her academic journey, reinforcing her dedication to excellence and innovation in veterinary and genetic research.

Research Focus

Assist. Prof. Dr. Asmaa Yehia Ammar specializes in genetics and genetic engineering 🧬, with a strong research focus on environmental stressors and gene expression in animal reproduction and aquatic species 🐟🧫. Her studies explore how factors like low-oxygen environments, thermal stress, and climate variation influence reproductive function, immune responses, and molecular gene regulation in organisms like mice and Nile tilapia 🐭🌡️. Her work bridges molecular biology, veterinary science, and environmental physiology, contributing to advances in animal health, biotechnology, and reproductive genetics 🌍📈. Her research is vital for climate-resilient livestock and aquatic health strategies.

Publication Top Notes

Ammar, A. Y., Minisy, F. M., Shawki, H. H., Mansour, M., Hemeda, S. A., El Nahas, A. F., … & Oishi, H. (2024). Exposure to a Low-Oxygen Environment Causes Implantation Failure and Transcriptomic Shifts in Mouse Uteruses and Ovaries. Biomedicines, 12(5), 1016.

Ammar, A. Y., El Nahas, A. F., Mahmoud, S., Barakat, M. E., & Hassan, A. M. (2018). Characterization of type IV antifreeze gene in Nile tilapia (Oreochromis niloticus) and influence of cold and hot weather on its expression and some immune-related genes. Fish physiology and biochemistry, 44, 515-525.

Hassan, A. M., El Nahas, A. F., Mahmoud, S., Barakat, M. E., & Ammar, A. Y. (2017).　Thermal stress of ambient temperature modulate expression of stress and immune-related　genes and DNA fragmentation in Nile tilapia (Oreochromis niloticus (Linnaeus,　1758)). Appl. Ecol. Environ. Res, 15(3), 1343-1354.

Elbialy, Z. I., El-Nahas, A. F., Elkatatny, N. A., & Ammar, A. Y. (2016). Quantitative　expression analysis of myostatin gene in Nile Tilapia (Oreochromis niloticus) tissues in　adult stage. Alexandria Journal of Veterinary Sciences, 51(1), 170-173

Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Posted on by Top Pharmaceutical

Hongwei Yao | Gastrointestinal Pharmacology | Best Researcher Award

Prof. Hongwei Yao, capital medical university Affiliated Beijing Friendship Hospital, China

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a renowned gastrointestinal surgeon with over 20 years of experience in diagnosing and treating GI tumors. 💉 He excels in laparoscopic and transanal endoscopic microsurgery (TEM) 🩺 and has led multiple research studies, authoring 100+ academic papers 📚—90+ focused on colorectal surgery. 🧬 He is the lead translator of Standard Laparoscopic Surgery for Upper GI Tract and co-translator of the national textbook Colorectal and Anal Surgery. 🔬 Prof. Yao holds two utility model patents for surgical innovations and continues to pioneer breakthroughs in colorectal cancer treatment. 🧠 His work bridges clinical expertise and cutting-edge research.

Publication Profile 

Orcid

Education

Prof. Dr. Hongwei Yao 🧑‍⚕️ is a distinguished gastrointestinal surgeon with over 20 years of clinical excellence in diagnosing and treating GI tumors 🧬. An expert in advanced surgical techniques such as laparoscopic surgery and transanal endoscopic microsurgery (TEM) 🔍, he is known for handling complex gastrointestinal procedures with precision. He has led numerous research projects and authored more than 100 academic papers 📚, with over 90 focusing on colorectal surgery. He served as lead translator of Standard Laparoscopic Surgery for Upper GI Tract 📘 and co-translator of Colorectal and Anal Surgery 📖. Prof. Yao also holds two utility model patents .

Editorial Appointments

Prof. Hongwei Yao 🧑‍⚕️ holds esteemed editorial roles in several leading medical journals. Since December 2019, he has served as Associate Editor for the Diseases of the Colon & Rectum journal 🧻, which is indexed in SSCI. Additionally, he has been a dedicated Editorial Board Member for the Chinese Journal of Inflammatory Bowel Diseases 💢 since February 2017, and for the Chinese Journal of Digestive Surgery 🩺 since July 2021, both indexed in CSCD and CSTPCD. These appointments reflect his profound expertise in gastrointestinal surgery and commitment to advancing medical research and literature 📚.

Research Focus

Prof. Hongwei Yao 🧑‍⚕️ focuses his groundbreaking research on colorectal cancer, gastrointestinal surgery, and translational oncology 🧬. His core interest lies in neoadjuvant therapies combining chemoradiation with immunotherapy (especially PD-1/PD-L1 blockade) for treating locally advanced rectal cancer 🎯. His innovative studies explore gut microbiota, nanomedicine, biospectroscopy, and surgical optimization to personalize cancer care 🧪. He also advances wound healing and stem cell therapies for post-surgical recovery 🩹. Through high-impact publications and clinical trials, Prof. Yao contributes to redefining standards in cancer diagnostics, surgical margins, and immune modulation in GI tumors ⚕️.

Publication Top Notes

Neoadjuvant chemoradiation with or without PD-1 blockade in locally advanced rectal cancer: a randomized phase 2 trial

Opportunities and challenges of indocyanine green in gastrointestinal cancers for intraoperative and nano-medicine application

Opportunities and challenges of nanomaterials in wound healing: Advances, mechanisms, and perspectives

Enhancing thromboprophylaxis after colorectal cancer surgery in China: Bridging the gap between evidence and implementation through pathway optimization

Exploring causal correlations between circulating levels of cytokines and colorectal cancer risk: A Mendelian randomization analysis

Gut microbiome model predicts response to neoadjuvant immunotherapy plus chemoradiotherapy in rectal cancer

Definition and grading of anastomotic leakage following right hemicolectomy

Perfusion outcomes with near-infrared indocyanine green imaging system in laparoscopic total mesorectal excision for mid-rectal or low-rectal cancer (POSTER): a study protocol

The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration

Josep Allué Creus | Regulatory Affairs | Best Researcher Award

Posted on by Top Pharmaceutical

Josep Allué Creus | Regulatory Affairs | Best Researcher Award

Prof. Dr. Josep Allué Creus, Apdena Consult, Spain

Prof. Dr. Josep Allué Creus 🧪🌿 is a renowned Doctor of Pharmacy and expert in phytotherapy. A retired Professor of Plant Physiology at the Universitat Autònoma de Barcelona 🎓, he co-directs the Master’s and Postgraduate Programs in Phytotherapy at IL3, University of Barcelona 💻📘. He serves as the spokesperson for Medicinal Plants and Homeopathy at the College of Pharmacists of Barcelona 💊 and is a founding member and treasurer of SEFIT. As part of AEEM’s Natural Products group 👩‍⚕️, his research integrates botanical science and women’s health, making him a leader in herbal medicine 🌸🔬.

Publication Profile

Orcid

Education

Prof. Dr. Josep Allué Creus 🎓🧪 exemplifies academic excellence with a prestigious Doctorate in Pharmacy, laying the cornerstone for his remarkable contributions to the fields of phytotherapy and medicinal plant sciences 🌿📚. His doctoral foundation reflects a deep-rooted dedication to advancing healthcare through botanical knowledge and evidence-based research 🔬💊. Prof. Allué’s commitment to scientific integrity and innovation has positioned him as a respected authority in natural medicine 🌱, influencing both academic circles and clinical applications. His passion for teaching and research continues to inspire the next generation of pharmacists and phytotherapy experts across Spain and beyond 🌍👨‍🏫.

Experience

Prof. Dr. Josep Allué Creus 📘🌿 has made significant academic and teaching contributions as a Professor of Plant Physiology at the Universitat Autònoma de Barcelona 🏛️. Throughout his career, he nurtured and mentored countless students, shaping future generations of scientists, pharmacists, and healthcare professionals 👩‍⚕️🧑‍🔬. His passion for education did not end with retirement—he continues to share his expertise as a co-director of master’s and postgraduate programs in phytotherapy through IL3 at the University of Barcelona 🎓🌱. Prof. Allué’s unwavering dedication to lifelong learning and botanical sciences remains a beacon of inspiration in academic circles 🔬📖.

Research Focus

Prof. Dr. Josep Allué Creus 🧠🌿 focuses on two dynamic research domains: phytotherapy and neurodegenerative diseases. His pioneering work on medicinal plant extracts 🌱, such as hemp-derived compounds, highlights their therapeutic potential for conditions like gastrointestinal disorders and dyspepsia 💊. Parallelly, he contributes extensively to cutting-edge Alzheimer’s research, especially in biomarker development for early detection of cognitive decline 🧬🧪. His publications delve into plasma-based assays for amyloid and tau proteins, advancing non-invasive diagnostics in neurology 🧫🔍. Bridging natural medicine and modern neurobiology, Prof. Allué champions holistic innovation in health science.

Publication Top Notes

Hemp Extract (<i>Extractum Cannabis</i>) in the Treatment of Gastrointestinal Distress and Dyspepsia: Historical Insights from Barcelona, Spain

Clinical performance of an antibody-free assay for plasma Aβ42/Aβ40 to detect early alterations of Alzheimer’s disease in individuals with subjective cognitive decline

Clinical utility of an antibody-free LC-MS method to detect brain amyloid deposition in cognitively unimpaired individuals from the screening visit of the A4 Study

Contribution of clinical information to the predictive performance of plasma β-amyloid levels for amyloid positron emission tomography positivity

Detecting amyloid positivity in early Alzheimer’s disease using combinations of plasma Aβ42/Aβ40 and p-tau

Head-to-Head Comparison of 8 Plasma Amyloid-β 42/40 Assays in Alzheimer Disease

Individualized prognosis of cognitive decline and dementia in mild cognitive impairment based on plasma biomarker combinations

Performance of the plasma Aβ42/Aβ40 ratio, measured with a novel HPLC-MS/MS method, as a biomarker of amyloid PET status in a DPUK-KOREAN cohort

The global Alzheimer’s Association round robin study on plasma amyloid β methods

Plasma amyloid, phosphorylated tau, and neurofilament light for individualized risk prediction in mild cognitive impairment

Outstanding Phenotypic Differences in the Profile of Amyloid-β between Tg2576 and APPswe/PS1dE9 Transgenic Mouse Models of Alzheimer’s Disease

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Posted on by Top Pharmaceutical

Laura Weinstein | Drug Delivery Systems | Best Researcher Award

Ms. Laura Weinstein, University of Delaware, United States

Ms. Laura Weinstein is an accomplished biomedical engineering student at the University of Delaware 🎓, set to graduate in May 2025 with a stellar GPA of 3.97. With minors in nanoscale materials and chemistry 🧪, she has led impactful research in nanoparticle drug delivery, orthotic device innovation, and immunoengineering. Her work spans labs at Delaware and Vanderbilt 🏥, earning her top honors including the Eugene du Pont Memorial Scholarship and Best Poster Awards 🏆. Passionate about translational medicine, Laura’s dedication to improving healthcare through engineering solutions marks her as a rising star in biomedical research 🌟.

Publication Profile 

Google Scholar

Education

Ms. Laura Weinstein is currently pursuing an Honors Bachelor of Science in Biomedical Engineering at the University of Delaware, with expected graduation in May 2025 📅. She maintains an outstanding GPA of 3.97 🌟 and complements her major with minors in Nanoscale Materials and Chemistry ⚗️. Her coursework spans core sciences and advanced engineering, including Introductory Biology 🧬, General Chemistry 🧪, Physics ⚛️, and Biomedical Experimental Design 📊. She has also delved into Immunoengineering, Cell Engineering 🧫, Nanomaterials, and Nanomedicine 💉. Proficient in Python and MATLAB 💻, Laura combines technical skills with scientific curiosity, preparing her for groundbreaking biomedical research 🔬.

Awards

Ms. Laura Weinstein has received numerous prestigious honors throughout her academic journey. From 2021–2025, she was awarded the esteemed Eugene du Pont Memorial Scholarship 🎓, covering full tuition, housing, meals, and book expenses. In 2024, she earned 1st place for designing a prototype to secure thoracostomy tubes 🩺. She is also a National Cyber Scholar (2022–2024) 💻 and won the Biomedical Engineering Distinguished Sophomore Award in 2023 🧬. That same year, she was recognized by the Delaware Department of Technology and Information 📡. In 2022, she placed 1st in the Ratcliffe Eco Entrepreneurship Innovation Sprint 🌱🚀

Experience

Ms. Laura Weinstein has been actively engaged in cutting-edge research at the University of Delaware’s Day Lab since January 2022 🏛️. Under the mentorship of Dr. Emily Day and PhD candidate Eric Sterin 👩‍🏫, she developed polymeric nanoparticles for biomimetic cargo delivery via cancer cell membranes 🧫. She contributed to refining purification protocols for DiD-fluorescent nanoparticles 💡 and guided fellow undergraduates in research techniques 📘. Her dedication extended beyond semesters, participating in multiple research fellowships and programs including the 2022 CBER Summer Scholars REU, 2023 Winter Fellowship, and 2024–2025 Summer/Winter Fellowships 🧪📊—highlighting her passion for biomedical innovation.

Research Focus

Ms. Laura Weinstein focuses her research in the dynamic field of biomedical nanotechnology and targeted drug delivery 🧪. Her studies explore cell biomimicry, using cancer cell membranes to improve therapeutic delivery for hematological cancers 🧫🩸. She also investigates nanoparticle purification challenges, ensuring enhanced precision in drug transport systems 🎯. Her work integrates principles of nanomedicine, immunoengineering, and materials science to develop innovative approaches in cancer treatment and diagnostics 🧬. Through her publications and lab experience, Laura contributes to advancing next-generation polymeric nanoparticle technologies—blending engineering and biology to revolutionize patient care and medical outcomes 🚀💊.

Publication Top Notes

Hiding in Plain Sight: Cell Biomimicry for Improving Hematological Cancer Outcomes

Standard purification methods are not sufficient to remove micellular lipophilic dye from polymer nanoparticle solution